Logo image of JAZZ

JAZZ PHARMACEUTICALS PLC (JAZZ) Stock Fundamental Analysis

NASDAQ:JAZZ - Nasdaq - IE00B4Q5ZN47 - Common Stock

121.43  +0.25 (+0.21%)

After market: 121.43 0 (0%)

Fundamental Rating

6

Taking everything into account, JAZZ scores 6 out of 10 in our fundamental rating. JAZZ was compared to 195 industry peers in the Pharmaceuticals industry. JAZZ scores excellent on profitability, but there are some minor concerns on its financial health. JAZZ may be a bit undervalued, certainly considering the very reasonable score on growth With these ratings, JAZZ could be worth investigating further for value investing!.


Dividend Valuation Growth Profitability Health

Quickly go to:

7

1. Profitability

1.1 Basic Checks

JAZZ had positive earnings in the past year.
JAZZ had a positive operating cash flow in the past year.
In multiple years JAZZ reported negative net income over the last 5 years.
JAZZ had a positive operating cash flow in each of the past 5 years.
JAZZ Yearly Net Income VS EBIT VS OCF VS FCFJAZZ Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 500M 1B

1.2 Ratios

JAZZ has a Return On Assets of 3.78%. This is amongst the best in the industry. JAZZ outperforms 86.56% of its industry peers.
JAZZ's Return On Equity of 11.10% is amongst the best of the industry. JAZZ outperforms 89.78% of its industry peers.
Looking at the Return On Invested Capital, with a value of 4.95%, JAZZ belongs to the top of the industry, outperforming 81.72% of the companies in the same industry.
JAZZ had an Average Return On Invested Capital over the past 3 years of 3.02%. This is significantly below the industry average of 43.99%.
The last Return On Invested Capital (4.95%) for JAZZ is above the 3 year average (3.02%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 3.78%
ROE 11.1%
ROIC 4.95%
ROA(3y)-0.37%
ROA(5y)2.4%
ROE(3y)-1.49%
ROE(5y)3.77%
ROIC(3y)3.02%
ROIC(5y)4.82%
JAZZ Yearly ROA, ROE, ROICJAZZ Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 5 -5 10 15 20

1.3 Margins

JAZZ's Profit Margin of 11.60% is amongst the best of the industry. JAZZ outperforms 87.63% of its industry peers.
JAZZ's Profit Margin has declined in the last couple of years.
JAZZ has a better Operating Margin (17.62%) than 84.95% of its industry peers.
In the last couple of years the Operating Margin of JAZZ has declined.
Looking at the Gross Margin, with a value of 89.37%, JAZZ belongs to the top of the industry, outperforming 92.47% of the companies in the same industry.
In the last couple of years the Gross Margin of JAZZ has remained more or less at the same level.
Industry RankSector Rank
OM 17.62%
PM (TTM) 11.6%
GM 89.37%
OM growth 3Y-6.66%
OM growth 5Y-12.64%
PM growth 3Y2.34%
PM growth 5Y-14.48%
GM growth 3Y-1.83%
GM growth 5Y-1.08%
JAZZ Yearly Profit, Operating, Gross MarginsJAZZ Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 40 60 80

More info and screens

5

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so JAZZ is destroying value.
The number of shares outstanding for JAZZ has been reduced compared to 1 year ago.
JAZZ has more shares outstanding than it did 5 years ago.
The debt/assets ratio for JAZZ has been reduced compared to a year ago.
JAZZ Yearly Shares OutstandingJAZZ Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M
JAZZ Yearly Total Debt VS Total AssetsJAZZ Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2B 4B 6B 8B 10B

2.2 Solvency

Based on the Altman-Z score of 1.50, we must say that JAZZ is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.50, JAZZ is in the better half of the industry, outperforming 62.90% of the companies in the same industry.
The Debt to FCF ratio of JAZZ is 5.55, which is a neutral value as it means it would take JAZZ, 5.55 years of fcf income to pay off all of its debts.
JAZZ has a better Debt to FCF ratio (5.55) than 86.56% of its industry peers.
A Debt/Equity ratio of 1.46 is on the high side and indicates that JAZZ has dependencies on debt financing.
The Debt to Equity ratio of JAZZ (1.46) is worse than 76.34% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.46
Debt/FCF 5.55
Altman-Z 1.5
ROIC/WACC0.78
WACC6.32%
JAZZ Yearly LT Debt VS Equity VS FCFJAZZ Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2B 4B 6B

2.3 Liquidity

JAZZ has a Current Ratio of 4.26. This indicates that JAZZ is financially healthy and has no problem in meeting its short term obligations.
JAZZ's Current ratio of 4.26 is fine compared to the rest of the industry. JAZZ outperforms 61.29% of its industry peers.
JAZZ has a Quick Ratio of 3.74. This indicates that JAZZ is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 3.74, JAZZ is in line with its industry, outperforming 59.14% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.26
Quick Ratio 3.74
JAZZ Yearly Current Assets VS Current LiabilitesJAZZ Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 1B 2B 3B

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 48.22% over the past year.
JAZZ shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 6.00% yearly.
The Revenue has been growing slightly by 5.23% in the past year.
Measured over the past years, JAZZ shows a quite strong growth in Revenue. The Revenue has been growing by 15.19% on average per year.
EPS 1Y (TTM)48.22%
EPS 3Y13.68%
EPS 5Y6%
EPS Q2Q%36.57%
Revenue 1Y (TTM)5.23%
Revenue growth 3Y17.5%
Revenue growth 5Y15.19%
Sales Q2Q%8.52%

3.2 Future

JAZZ is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.14% yearly.
The Revenue is expected to grow by 5.77% on average over the next years.
EPS Next Y13.27%
EPS Next 2Y10.18%
EPS Next 3Y7.79%
EPS Next 5Y8.14%
Revenue Next Year5.42%
Revenue Next 2Y6.13%
Revenue Next 3Y5.5%
Revenue Next 5Y5.77%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
JAZZ Yearly Revenue VS EstimatesJAZZ Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1B 2B 3B 4B 5B
JAZZ Yearly EPS VS EstimatesJAZZ Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 5 10 15 20 25

More info and screens

9

4. Valuation

4.1 Price/Earnings Ratio

JAZZ is valuated cheaply with a Price/Earnings ratio of 6.19.
Based on the Price/Earnings ratio, JAZZ is valued cheaply inside the industry as 96.77% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 28.29, JAZZ is valued rather cheaply.
The Price/Forward Earnings ratio is 5.46, which indicates a rather cheap valuation of JAZZ.
JAZZ's Price/Forward Earnings ratio is rather cheap when compared to the industry. JAZZ is cheaper than 95.70% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 24.44, JAZZ is valued rather cheaply.
Industry RankSector Rank
PE 6.19
Fwd PE 5.46
JAZZ Price Earnings VS Forward Price EarningsJAZZ Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, JAZZ is valued cheaper than 91.40% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, JAZZ is valued cheaper than 95.70% of the companies in the same industry.
Industry RankSector Rank
P/FCF 6.66
EV/EBITDA 7.7
JAZZ Per share dataJAZZ EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 40 -40 60

4.3 Compensation for Growth

JAZZ's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of JAZZ may justify a higher PE ratio.
PEG (NY)0.47
PEG (5Y)1.03
EPS Next 2Y10.18%
EPS Next 3Y7.79%

More info and screens

0

5. Dividend

5.1 Amount

JAZZ does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

JAZZ PHARMACEUTICALS PLC

NASDAQ:JAZZ (1/21/2025, 8:09:00 PM)

After market: 121.43 0 (0%)

121.43

+0.25 (+0.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06 2024-11-06/amc
Earnings (Next)N/A N/A
Inst Owners96.94%
Inst Owner Change0.1%
Ins Owners2.36%
Ins Owner Change1.11%
Market Cap7.34B
Analysts82.4
Price Target184.34 (51.81%)
Short Float %6.56%
Short Ratio6.1
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.36%
Min EPS beat(2)8.88%
Max EPS beat(2)17.85%
EPS beat(4)2
Avg EPS beat(4)-3.87%
Min EPS beat(4)-37.13%
Max EPS beat(4)17.85%
EPS beat(8)2
Avg EPS beat(8)-18.7%
EPS beat(12)5
Avg EPS beat(12)-10.98%
EPS beat(16)8
Avg EPS beat(16)-6.21%
Revenue beat(2)0
Avg Revenue beat(2)-0.1%
Min Revenue beat(2)-0.19%
Max Revenue beat(2)-0.02%
Revenue beat(4)0
Avg Revenue beat(4)-2.1%
Min Revenue beat(4)-7.3%
Max Revenue beat(4)-0.02%
Revenue beat(8)0
Avg Revenue beat(8)-1.84%
Revenue beat(12)2
Avg Revenue beat(12)-1.68%
Revenue beat(16)3
Avg Revenue beat(16)-1.36%
PT rev (1m)2.1%
PT rev (3m)2.87%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-0.01%
EPS NY rev (1m)0%
EPS NY rev (3m)3.84%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-3.31%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.12%
Valuation
Industry RankSector Rank
PE 6.19
Fwd PE 5.46
P/S 1.84
P/FCF 6.66
P/OCF 6.3
P/B 1.76
P/tB N/A
EV/EBITDA 7.7
EPS(TTM)19.61
EY16.15%
EPS(NY)22.24
Fwd EY18.32%
FCF(TTM)18.23
FCFY15.01%
OCF(TTM)19.27
OCFY15.87%
SpS66.05
BVpS69
TBVpS-45.95
PEG (NY)0.47
PEG (5Y)1.03
Profitability
Industry RankSector Rank
ROA 3.78%
ROE 11.1%
ROCE 6.27%
ROIC 4.95%
ROICexc 6.46%
ROICexgc 33.51%
OM 17.62%
PM (TTM) 11.6%
GM 89.37%
FCFM 27.6%
ROA(3y)-0.37%
ROA(5y)2.4%
ROE(3y)-1.49%
ROE(5y)3.77%
ROIC(3y)3.02%
ROIC(5y)4.82%
ROICexc(3y)3.45%
ROICexc(5y)6.29%
ROICexgc(3y)24.22%
ROICexgc(5y)39.58%
ROCE(3y)3.82%
ROCE(5y)6.1%
ROICexcg growth 3Y-9.45%
ROICexcg growth 5Y-18.29%
ROICexc growth 3Y-15.61%
ROICexc growth 5Y-12.76%
OM growth 3Y-6.66%
OM growth 5Y-12.64%
PM growth 3Y2.34%
PM growth 5Y-14.48%
GM growth 3Y-1.83%
GM growth 5Y-1.08%
F-Score7
Asset Turnover0.33
Health
Industry RankSector Rank
Debt/Equity 1.46
Debt/FCF 5.55
Debt/EBITDA 4.49
Cap/Depr 9.66%
Cap/Sales 1.57%
Interest Coverage 250
Cash Conversion 85.98%
Profit Quality 237.89%
Current Ratio 4.26
Quick Ratio 3.74
Altman-Z 1.5
F-Score7
WACC6.32%
ROIC/WACC0.78
Cap/Depr(3y)31.37%
Cap/Depr(5y)55.93%
Cap/Sales(3y)5.4%
Cap/Sales(5y)8.14%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)48.22%
EPS 3Y13.68%
EPS 5Y6%
EPS Q2Q%36.57%
EPS Next Y13.27%
EPS Next 2Y10.18%
EPS Next 3Y7.79%
EPS Next 5Y8.14%
Revenue 1Y (TTM)5.23%
Revenue growth 3Y17.5%
Revenue growth 5Y15.19%
Sales Q2Q%8.52%
Revenue Next Year5.42%
Revenue Next 2Y6.13%
Revenue Next 3Y5.5%
Revenue Next 5Y5.77%
EBIT growth 1Y265.16%
EBIT growth 3Y9.68%
EBIT growth 5Y0.62%
EBIT Next Year6.91%
EBIT Next 3Y5.28%
EBIT Next 5Y8.56%
FCF growth 1Y11.97%
FCF growth 3Y26.33%
FCF growth 5Y9.47%
OCF growth 1Y5.14%
OCF growth 3Y6.67%
OCF growth 5Y6.45%